Bernard Chatelain Selected Research

Activated Protein C Resistance (APC Resistance)

4/2018	Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests.
12/2012	Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bernard Chatelain Research Topics

Disease

5	Venous Thromboembolism 12/2018 - 01/2013
4	Thrombosis (Thrombus) 07/2019 - 05/2012
4	Neoplasms (Cancer) 07/2013 - 01/2003
3	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 07/2019 - 09/2015
3	Hemolysis 12/2018 - 09/2015
3	Disseminated Intravascular Coagulation 12/2018 - 03/2014
2	Activated Protein C Resistance (APC Resistance) 04/2018 - 12/2012
2	Thrombocytopenia (Thrombopenia) 12/2016 - 06/2010
1	Liver Failure 10/2020
1	Thrombophilia 04/2018
1	Hemorrhage 01/2015
1	Acute Promyelocytic Leukemia 03/2014
1	Acute Kidney Injury (Acute Renal Failure) 02/2014
1	Stroke (Strokes) 01/2014
1	Atrial Fibrillation 01/2014
1	Breast Neoplasms (Breast Cancer) 01/2013
1	Inflammation (Inflammations) 12/2012
1	Ischemia 12/2012
1	Hypoxia (Hypoxemia) 12/2012
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2012
1	Chromosome Aberrations (Chromosome Abnormalities) 05/2012
1	Genomic Instability 05/2012
1	Tics (Tic) 03/2012
1	Crohn Disease (Crohn's Disease) 01/2012
1	Hereditary Spherocytosis 07/2011
1	Drug-Related Side Effects and Adverse Reactions 01/2009
1	Lymphatic Metastasis 01/2003
1	Carcinoma (Carcinomatosis) 01/2003
1	Squamous Cell Carcinoma of Head and Neck 01/2003
1	Refractory Anemia with Excess of Blasts (RAEM) 10/2002
1	Refractory Anemia 10/2002
1	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 10/2002

Drug/Important Bio-Agent (IBA)

4	eculizumab FDA Link 07/2019 - 09/2015
4	Biomarkers (Surrogate Marker)IBA 12/2018 - 01/2013
4	AnticoagulantsIBA 04/2018 - 01/2014
3	Indicators and Reagents (Reagents)IBA 10/2020 - 05/2012
3	Thrombin FDA Link 01/2018 - 03/2012
2	fibrin fragment D (D-dimer)IBA 12/2018 - 06/2014
2	Complement System Proteins (Complement)IBA 08/2017 - 09/2015
2	Dacarbazine (DIC)FDA LinkGeneric 02/2017 - 03/2014
2	Thromboplastin (Tissue Factor)IBA 02/2017 - 01/2013
2	Heparin (Liquaemin)FDA LinkGeneric 12/2016 - 06/2010
2	RivaroxabanIBA 01/2015 - 12/2012
1	Prothrombin (Factor II)IBA 10/2020
1	Complement C5 (Complement 5)IBA 12/2018
1	Factor Xa InhibitorsIBA 07/2018
1	Protein SIBA 04/2018
1	Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA 04/2018
1	AntithrombinsIBA 04/2018
1	Protein CIBA 04/2018
1	argatroban (MPQA)FDA Link 12/2016
1	apixabanIBA 01/2015
1	A 7 (A-7)IBA 01/2013
1	Fibrinogen (Factor I)FDA Link 12/2012
1	Clonidine (ST 155)FDA LinkGeneric 12/2012
1	Blood Coagulation Factors (Coagulation Factor)IBA 12/2012
1	Antithrombin ProteinsIBA 12/2012
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 10/2012
1	A-Form DNA (A-DNA)IBA 05/2012
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 05/2012
1	Dabigatran FDA Link 05/2012
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2012
1	Azathioprine (Imuran)FDA LinkGeneric 01/2012
1	Lipid Bilayers (Lipid Bilayer)IBA 07/2011
1	Purine NucleosidesIBA 01/2009
1	Proteins (Proteins, Gene)FDA Link 01/2003
1	Cadherins (E-Cadherin)IBA 01/2003
1	Cell Adhesion MoleculesIBA 01/2003
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2003
1	DNA (Deoxyribonucleic Acid)IBA 01/2003
1	HLA-DR Antigens (HLA-DR)IBA 10/2002

Therapy/Procedure

2	Therapeutics 12/2018 - 01/2012
1	Drug Therapy (Chemotherapy) 01/2009